Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A recall of products produced at Abbott's Sturgis, Michigan facility has contributed to a nationwide shortage of baby formula.

Abbott says if the FDA were to re-open its Michigan facility to address baby formula shortage, it would still take months to get more on shelves

Abbott Nutrition said Friday it has bolstered production at its baby formula manufacturing plants in Ireland and Michigan in an effort to ease the shortages exacerbated by the shutdown of its

Baby formula shortage has Abbott leaning on Ireland, Ohio factories

Abbott Laboratories ABT, +1.40% said Friday that it will pay rebates for other infant formula products similar to Similac through August as a result of the current formula shortage caused in part by a recall at its plant in Michigan. The company has infant formula contracts with the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).

Abbott to extend baby formula rebates until at least Aug. 31

The U.S. Centers for Disease Control and Prevention (CDC) has closed its investigation on Abbott Laboratories' infant formula, with no additional cases of infections, according to a notice on the U.S. Food and Drug Administration website.

U.S. CDC closes investigation on Abbott's infant formula

Abbott Laboratories' appeal goes beyond its market-beating 1.8% dividend yield.

Here's Why This Dividend King Is a Buy for Income Investors

The company said it could resume production within two weeks.

Baby Formula Shortages Are Bad for Parents. They Could Be Good for Abbott Stock.

AbbVie

Easterly Government Properties

You can really think long term with these great dividend stocks.

3 Dividend Stocks You Can Buy and Hold for Decades

A whistleblower report released last month showed a former Abbott employee brought concerns about the facility months before the FDA issued a recall.

Baby Formula Shortage: How Safety Concerns At An Abbott Facility Fueled A Crisis

Abbott Nutrition, a major U.S. formula manufacturer, says it will be at least two months before baby formula made at its closed Sturgis, Michigan, plant will hit stores shelves after it reopens "subject to FDA approval."

Abbott says it will be at least two months before baby formula from shuttered plant hits shelves

Abbott Laboratories said on Wednesday it could restart production of infant formula at its troubled Michigan facility within two weeks.

Abbott could restart infant formula production at Michigan plant

Abbott Laboratories ABT, -0.42% said it can restart production of its baby formulas at a plant in Michigan within two weeks if U.S. regulators allow it to do so.

As a shortage worsens, Abbott says it can get baby formula back on store shelves in June

New partnership will provide physician training to drive improved diversity in clinical trials Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists Provides opportunities for underrepresented physicians to receive training on the clinical trials process, learn new skills, expand their networks and increase visibility with industry partners ABBOTT PARK, Ill., May 11, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups.

Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials

Alcon Inc. - Registered Shares

Canopy Growth

Haemonetics

Intuitive Surgical

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.

3 Medical Product Stocks Set to Beat on Earnings This Season

There are choppy waters ahead, but plenty of opportunity on the horizon.

What's Next for Abbott Laboratories' Stock?

Abbott's Q1 2022 earnings support a strong buy thesis for this perennial outperformer, with all segments save nutrition performing at peak levels. Abbott's new product pipeline has provided epic pandemic performance as it continues to produce and refresh Abbott's revenues.

Abbott: Solid Conviction Pick

The strong quarter wasn't just due to an increase in COVID-19 revenue.

Here's How Abbott Laboratories Increased Its Profits by 37% in Q1

Johnson & Johnson

Where's the safer place to park your money?

Better Dividend King: Johnson & Johnson vs. Abbott Laboratories

Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity™ m system, which provides fast results in high volumes – detecting four infections simultaneously Test provides a critically important tool as people return to regular STI testing; a pause in testing during the pandemic contributed to an increase of STI cases 1,2 Pandemic has shown value of at-home testing and sample collection, and Abbott plans to bring that convenience and discretion to additional areas in the future, including for STIs ABBOTT PARK, Ill., May 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received FDA clearance for its Alinity™ m STI Assay.

Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise

Metabolic nutrition formulas previously on hold will be released free of charge to patients, in coordination with healthcare professionals based on need and on a case-by-case basis The lots being released were not included in the February recall and are now being released at the request of the U.S. FDA Patients, caregivers and healthcare professionals with questions should contact Abbott at +1-800-881-0876 ABBOTT PARK, Ill., April 29, 2022 /PRNewswire/ -- At the request of the U.S. Food and Drug Administration (FDA), Abbott (NYSE: ABT) is releasing limited quantities of metabolic nutrition formulas that were previously on hold following Abbott's recall of some powder infant formulas from its Sturgis, Mich.

Abbott to Release Metabolic Nutrition Formulas

Treatment with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ resulted in patients with persistent atrial fibrillation experiencing an improved quality of life The catheter is part of Abbott's suite of electrophysiology solutions designed to improve procedures to address cardiac arrythmias ABBOTT PARK, Ill., April 29, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the PERSIST-END study, which showed that nearly nine out of 10 patients (89%) treated for persistent atrial fibrillation (AFib) with the company's TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) remained symptom-free for up to 15 months following the procedure.

Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months

Pfizer

UnitedHealth Group

Walgreens

People will always need medical treatment regardless of what is going on with the economy, which makes stocks in the healthcare sector consistently reliable investments.

The 5 Best Healthcare Stocks To Own Right Now

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., Abbott's steerable sheath offers precise and flexible placement when used with the company's Amplatzer Amulet LAA Occluder ABBOTT PARK, Ill., April 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. availability of its Amplatzer™ Steerable Delivery Sheath, which is used with the company's Amplatzer Amulet™ Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.

Abbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Company's Amulet™ Device

Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin (HbA1c) at three months1 Reductions in HbA1c followed a similar pattern in people with both type 1 and type 2 diabetes and were sustained for up to 24 months1 Meta-analysis shows that people with type 2 diabetes who use insulin benefit from the FreeStyle Libre system in the same way as people with type 1 diabetes in real-world studies1, showing the need for access to the latest glucose monitoring technology ABBOTT PARK, Ill., April 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from a new meta-analysis of 75 real-world, observational studies demonstrating that its FreeStyle® Libre system provides significant reductions in glycated hemoglobin (HbA1c) that are sustained up to 24 months in adults with both type 1 and type 2 diabetes.1 People with type 2 diabetes who use insulin are often restricted when it comes to access to continuous glucose monitoring, but both clinical trials and real-world studies demonstrate significant improvement of glycemic control.

New Analysis Shows that Abbott's FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes

The three companies will work to accelerate development of automated insulin delivery system for people living with diabetes System is being designed to include Abbott's FreeStyle Libre® 3 sensor, CamDiab's CamAPS FX algorithm, and Ypsomed's mylife™ YpsoPump® Partnership demonstrates the companies' collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes BARCELONA, Spain, April 27, 2022 /PRNewswire/ -- Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European countries.

Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes

ABBOTT PARK, Ill., April 26, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC) to purchase up to 1,000,000 Abbott common shares, representing approximately 0.06% of the company's outstanding shares.

News for Abbott Labs Stock (ABT)